Aerie Pharmaceuticals Inc. (AERI) announced after the bell Wednesday that its Phase 3 clinical trial of RoclatanTM achieved its primary efficacy endpoint. Roclatan is an investigational glaucoma drug.
from RTT - Before the Bell http://ift.tt/2cvNLs1
via IFTTT
No comments:
Post a Comment